Hepatic profile analyses of tipranavir in Phase II and III clinical trials by Mikl, Jaromir et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
BMC Infectious Diseases
Open Access Research article
Hepatic profile analyses of tipranavir in Phase II and III clinical trials
Jaromir Mikl*1,2, Mark S Sulkowski3, Yves Benhamou4, Douglas Dieterich5, 
Stanislas Pol6, Jürgen Rockstroh7, Patrick A Robinson2, Mithun Ranga2 and 
Jerry O Stern2
Address: 1SUNY at Albany, School of Public Health, Rensselaer NY, USA, 2Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, 
3Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, USA, 4Service d'Hépato-Gastroentérologie, Hôpital 
Pitié-Salpêtrière, Paris, France, 5Mount Sinai School of Medicine, New York, New York, USA, 6Hôpital Necker, APHP, Unité d'Hépatologie, Paris, 
France and 7Department of Medicine I, University of Bonn, Bonn, Germany
Email: Jaromir Mikl* - jmikl1@nycap.rr.com; Mark S Sulkowski - msulkowski@jhmi.edu; Yves Benhamou - ybenhamou@teaser.fr; 
Douglas Dieterich - douglas.dieterich@msnyuhealth.org; Stanislas Pol - stanislas.pol@cch.aphp.fr; 
Jürgen Rockstroh - Juergen.Rockstroh@ukb.uni-bonn.de; Patrick A Robinson - patrick.robinson@boehringer-ingelheim.com; 
Mithun Ranga - mithun.ranga@boehringer-ingelheim.com; Jerry O Stern - jerry.stern@boehringer-ingelheim.com
* Corresponding author    
Abstract
Background: The risk and course of serum transaminase elevations (TEs) and clinical hepatic
serious adverse event (SAE) development in ritonavir-boosted tipranavir (TPV/r) 500/200 mg BID
recipients, who also received additional combination antiretroviral treatment agents in clinical trials
(TPV/r-based cART), was determined.
Methods: Aggregated transaminase and hepatic SAE data through 96 weeks of TPV/r-based cART
from five Phase IIb/III trials were analyzed. Patients were categorized by the presence or absence
of underlying liver disease (+LD or -LD). Kaplan-Meier (K-M) probability estimates for time-to-first
US National Institutes of Health, Division of AIDS (DAIDS) Grade 3/4 TE and clinical hepatic SAE
were determined and clinical actions/outcomes evaluated. Risk factors for DAIDS Grade 3/4 TE
were identified through multivariate Cox regression statistical modeling.
Results: Grade 3/4 TEs occurred in 144/1299 (11.1%) patients; 123/144 (85%) of these were
asymptomatic; 84% of these patients only temporarily interrupted treatment or continued, with
transaminase levels returning to Grade ≤ 2. At 96 weeks of study treatment, the incidence of Grade
3/4 TEs was higher among the +LD (16.8%) than among the -LD (10.1%) patients. K-M analysis
revealed an incremental risk for developing DAIDS Grade 3/4 TEs; risk was greatest through 24
weeks (6.1%), and decreasing thereafter (>24-48 weeks: 3.4%, >48 weeks-72 weeks: 2.0%, >72-96
weeks: 2.2%), and higher in +LD than -LD patients at each 24-week interval. Treatment with TPV/
r, co-infection with hepatitis B and/or C, DAIDS grade >1 TE and CD4+ > 200 cells/mm3 at baseline
were found to be independent risk factors for development of DAIDS Grade 3/4 TE; the hazard
ratios (HR) were 2.8, 2.0, 2.1 and 1.5, respectively. Four of the 144 (2.7%) patients with Grade 3/
4 TEs developed hepatic SAEs; overall, 14/1299 (1.1%) patients had hepatic SAEs including six with
hepatic failure (0.5%). The K-M risk of developing hepatic SAEs through 96 weeks was 1.4%; highest
risk was observed during the first 24 weeks and decreased thereafter; the risk was similar between
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+LD and -LD patients for the first 24 weeks (0.6% and 0.5%, respectively) and was higher for +LD
patients, thereafter.
Conclusion: Through 96 weeks of TPV/r-based cART, DAIDS Grade 3/4 TEs and hepatic SAEs
occurred in approximately 11% and 1% of TPV/r patients, respectively; most (84%) had no
significant clinical implications and were managed without permanent treatment discontinuation.
Among the 14 patients with hepatic SAE, 6 experienced hepatic failure (0.5%); these patients had
profound immunosuppression and the rate appears higher among hepatitis co-infected patients.
The overall probability of experiencing a hepatic SAE in this patient cohort was 1.4% through 96
weeks of treatment. Independent risk factors for DAIDS Grade 3/4 TEs include TPV/r treatment,
co-infection with hepatitis B and/or C, DAIDS grade >1 TE and CD4+ > 200 cells/mm3 at baseline.
Trial registration: US-NIH Trial registration number: NCT00144170
Background
The introduction of highly active antiretroviral therapy
(HAART) is responsible for a substantial decline in AIDS
progression, opportunistic infections and mortality in
HIV-1-infected individuals in recent years [1-3]. However,
in the presence of antiretroviral (ARV) drugs and non-
adherence, resistant strains emerge and contribute to ther-
apeutic failure [4]. Tipranavir (TPV; Aptivus® is a next-gen-
eration protease inhibitor (PI), used in combination with
low-dose ritonavir (RTV;/r) in combination with other
background antiretroviral agents (TPV/r-based cART) for
treatment-experienced, HIV-1 infected patients with
resistance to more than one PI. TPV/r has shown sustained
activity against viruses with up to 20 PI mutations [5].
However, TPV/r-based cART use is associated with a risk of
elevated serum levels of alanine aminotransferase (ALT)
and/or aspartate aminotransferase (AST) transaminases
[6].
In general, HAART may be associated with elevated serum
transaminases [7]. The reported incidence of severe
transaminase elevations associated with HAART varies
from a low of 2% to as high as 18% [8]. However, reports
from other investigators indicate that as many as 6%-30%
of ARV treated patients, particularly those receiving pro-
tease inhibitors, may experience significant increases in
serum liver enzymes and consequently may have to dis-
continue treatment [9,10]. Patients co-infected with viral
hepatitis are at increased risk for hepatotoxicity [8,11-13].
Considering that between 10% - 50% of HIV infected per-
sons in the US and Europe are estimated to be co-infected
with HCV [14-17] hepatotoxicity becomes a challenge
when treating these patients. Severe hepatotoxicity occurs
in up to 6% of patients on HAART [7].
A recent study evaluated patients receiving PI-based ARV
therapy, with or without RTV co-administration [9]; the
risk of developing hepatotoxicity was similar across the
PIs evaluated and a boosting dose of RTV was associated
with a much lower risk than was observed with therapeu-
tic RTV dosing [9]. The study concluded that, while drug-
induced liver toxicity was an important consideration for
HIV treatment decisions, potential efficacy and pre-exist-
ing resistance primarily influence the selection of a cART
regimen [9]. In a recent report, the Kaplan-Meier (K-M)
risk estimates of US National Institutes of Health, Divi-
sion of AIDS (DAIDS) [18] Grade 3/4 ALT elevations were
9.9% and 2.8%, respectively, in patients treated with TPV/
r or RTV-boosted comparator PIs (CPI/r) in the large
Phase III RESIST trials at 48 weeks [19]. Multivariate anal-
yses in TPV/r-based cART patients indicated that the most
significant risk factors for Grade 3/4 ALT/AST levels in the
TPV/r and CPI/r groups were elevated baseline transami-
nases and hepatitis co-infection [19]. Others observed
similar results, identifying elevated transaminases at base-
line and/or hepatitis co-infection as risk factors associated
with liver toxicity among HIV infected patients treated
with antiretrovirals [20-24].
The current analysis is based largely on patients enrolled
in the RESIST trial, which demonstrated superior TPV/r
efficacy and durability in suppressing viral load (VL),
compared to CPI/r in more than 1400 patients with PI
resistance, advanced HIV infection and few, if any, other
treatment options [6].
The objective of this hepatic safety analysis was to evaluate
the risk and natural history of serum ALT/AST transami-
nase elevations and clinical hepatic serious adverse event
(SAE) development among treatment-experienced
patients receiving the approved standard dose of 500/200
mg BID TPV/r in Phase IIb and III trials through 96 weeks
of treatment. The development of DAIDS Grade 3/4 ALT/
AST elevations was further evaluated in patients catego-
rized as having underlying liver disease (+LD; baseline
transaminase elevations DAIDS Grade >1 [18] and/or
hepatitis B/C virus [HBV/HCV] co-infection) or no under-
lying liver disease (-LD; baseline transaminase elevations
Grade ≤ 1 and no HBV/HCV co-infection).BMC Infectious Diseases 2009, 9:203 http://www.biomedcentral.com/1471-2334/9/203
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Methods
Aggregated safety data were pooled from the five Phase IIb
and III trials which comprised the clinical development
program for TPV/r. Patients in these trials were highly
treatment-experienced and received the approved dose of
TPV/r 500/200 mg BID. The five trials in which these
patients were enrolled were two Phase II trials (1182.51
[N = 67], 1182.52 [n = 72]) [25,26], two pivotal Phase III
trials (1182.12 [RESIST 1, n = 311], 1182.48 [RESIST 2, n
= 436]) [6,27,28] and one "roll-over" trial (1182.17 [n =
413]) [29] that allowed patients from completed Phase II
trials to continue to receive TPV/r 500/200 mg BID and
provided TPV/r to those in RESIST who failed on the CPI/
r therapy. The RESIST-1 and RESIST-2 trials were open-
label, randomized trials that compared TPV/r with CPI/r
regimens in 21 countries in Europe, North and South
America, and Australia [6,27,28]. Trial 1182.52 was a ran-
domized, dose-selection trial thatcompared three dose
regimens of TPV/r, including the dose of 500/200 mg BID
[25]. Trial 1182.51 was a randomizedpharmacokinetic
and safety comparison of TPV/r versus CPI/r for 2 weeks,
followed by a dual-boosted regimen in patients who were
ineligible for the pivotal Phase III trials because of resist-
ance requirements [26].
All patients included in these five trials were HIV-1-
infected male and female adults (aged ≥ 18 years) with ≥
3 months of prior treatment with three classes of ARVs
(nucleoside reverse transcriptase inhibitors [NRTIs], non-
nucleoside reverse transcriptase inhibitors [NNRTIs], and
PIs), including at least two prior PI-based regimens (one
being the regimen at screening), who had a VL of ≥ 1000
copies/mL of plasma HIV-1 RNA at baseline. Patients with
HBV or HCV were eligible for inclusion if serum ALT/AST
transaminase levels were DAIDS Grade 2 (≤2.5 × the
upper limit of normal [ULN] reference range) or less [18].
Patients who were failing CPI/r in the RESIST trials or who
were treated with TPV/r in Phase II trials were allowed to
participate in the open-label TPV/r roll-over study
(1182.17) and were included in the hepatic safety analy-
ses.
All studies were designed and monitored in accordance
with the International Conference on Harmonization
guidance for Good Clinical Practice (ICH GCP) and writ-
ten informed consent was obtained from all study partic-
ipants. All study protocols, informed consent forms and
trial documentation was reviewed and approved by the
institutional review boards/local ethics committees of
participating centers.
The course of transaminase elevations and hepatic SAEs
through 96 weeks was characterized. Transaminase eleva-
tions were categorized according to NIH, DAIDS [18] sys-
tem for Grading the Severity of Adult and Pediatric
Adverse Events based on multiples of the Upper Limit of
Normal (ULN) reference range for ALT/AST: DAIDS Grade
0 defined as ALT/AST within normal range through < 1.25
× ULN; Grade 1 defined as mild elevation (1.25-2.5 ×
ULN); DAIDS Grade 2 defined as moderate elevation
(>2.5-5.0 × ULN); DAIDS Grade 3 defined as ALT/AST >
5-10 × ULN; and DAIDS Grade 4 defined as ALT/AST >10
× ULN. K-M probability estimates for time-to-first DAIDS
Grade 3/4 ALT/AST elevation and time-to-first clinical
hepatobiliary SAE were determined. Clinical actions and
outcomes following the development of DAIDS Grade 3/
4 transaminase elevation were analyzed with regards to
treatment continuation, interruption or discontinuation
of TPV/r.
Potential risk factors for DAIDS Grade 3/4 for ALT and/or
AST were assessed through multivariate Cox regression
statistical modeling and included all RESIST 1 and 2
patients (N = 1486) in order to compare TPV/r and CPI/r
treated patients.
Hepatobiliary adverse events (AEs) were defined as any AE
with a MedDRA (ver. 8.1) preferred term falling into hepa-
tobiliary system organ class (SOC) and included serious
and non-serious hepatobiliary AEs regardless of severity.
All of these events were considered to represent "sympto-
matic" AEs. Complete clinical profiles (all laboratory and
reported AEs from baseline throughout the participation
of the patient in the study) were created and underwent
medical review. Events were excluded as representing
symptomatic "hepatic" events if they were due to biliary
disease alone (e.g. cholecystitis, gallbladder cyst, choledo-
cholithiasis), hepatic neoplasm alone (primary or second-
ary), or if they represented only asymptomatic elevations
of liver laboratory tests, with the absence of any other
associated clinical AEs (e.g., fever, malaise, nausea,
abdominal pain, etc).
Patients were classified as +LD retrospectively by the pres-
ence of either chronic viral hepatitis and/or elevated
serum transaminases DAIDS Grade >1 at baseline [19].
Study protocols excluded patients with screening ALT/AST
elevation of Grade ≥ 2; however, some patients (n = 48)
who met the screening criteria were found to have DAIDS
Grade 2 elevations at baseline on the first study visit and
were included in the trials. Chronic HCV infection was
defined by the detection of HCV RNA. Chronic HBV infec-
tion was assessed at baseline by the presence of hepatitis
B surface antigen (HBV DNA was not measured). Patients
who were not co-infected with HBV or HCV and who had
baseline transaminase elevations of Grade 1 or less were
classified as -LD for these analyses.
Results
Baseline characteristics
Baseline characteristics of all study patients are presented
in Table 1. Data aggregated from the five TPV/r trials iden-BMC Infectious Diseases 2009, 9:203 http://www.biomedcentral.com/1471-2334/9/203
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tified 1299 treatment-experienced patients who received
the approved 500/200 mg BID dose of TPV/r. Of these,
1088 were classified as -LD patients and 179 as +LD
patients. The remaining 32 patients had either HBV/HCV
co-infection status or transaminase elevation data missing
at baseline and therefore are listed as unclassified and
were excluded from the +LD and -LD sub-analyses.
The patients were mostly males (86.5%) and there was
similar gender distribution between the risk groups (Table
1). The median baseline HIV-1 RNA and CD4+ cell counts
were similar between the two risk groups; -LD patients
had a median HIV-1 RNA level of 4.8 log10 copies/mL and
a median CD4+ cell count of 158 cells/mm3 at baseline,
+LD patients had a median HIV RNA of 4.7 log10 copies/
mL and a median CD4+ cell count of 151 cells/mm3 at
baseline.
Compared to patients who did not experience hepatic
SAEs, the 14 patients who experienced hepatic SAE were
slightly older, and presented with higher HIV RNA counts
and lower CD4+ counts at baseline (Table 1). All but one
of these patients responded to TPV/r treatment: the
median maximal reduction from baseline in HIV RNA
count was 5.3 log10 and the median maximal CD4+ count
increase from baseline was 74.5 cells/mm3  (data not
shown).
DAIDS Grade 3/4 ALT and/or AST transaminase elevations
In the aggregate Phase II and III TPV/r trials (n = 1299),
11.1% of TPV/r patients receiving 500/200 mg BID devel-
oped DAIDS Grade 3/4 ALT/AST elevations through 96
weeks of TPV/r-based cART treatment in the studies. The
incidence of DAIDS Grade 3/4 events was 11.1% (144/
1299 subjects); of these 6.9% were Grade 3 and 4.2% were
Grade 4 elevations.
Cumulative K-M estimates through 96 weeks of study
treatment for time-to-first DAIDS Grade 3/4 ALT/AST ele-
vations are presented in Table 2 and Figure 1. In the over-
all patient population, the cumulative risk of developing
a DAIDS Grade 3/4 ALT/AST elevation while on study
treatment was greatest in the first 24 weeks (6.1%) com-
pared to subsequent 24 week periods. The subsequent
Table 1: Demographic and baseline characteristics of TPV/r 500/200 mg patients in trials 1182.12, 1182.48, 1182.51, 1182.52 and 
1182.17 by risk
All TPV/r1
N = 1299
TPV/r -LD2
N = 1088
TPV/r +LD2
N = 179
TPV/r SAE
N = 14
Age (years):
Median 43 43 42 42
Range 17-80 17-80 18-72 35-63
Gender [N (%)]:
Male 1124 (86.5) 939 (86.3) 160 (89.4) 13 (92.9)
Female 175 (13.5) 149 (13.7) 19 (10.6) 1 (7.1)
Baseline HIV RNA (log10 copies/mL):
Median 4.8 4.8 4.7 4.9
Range 1.7-6.5 1.7-6.5 2.7-6.3 3.6-5.6
Baseline CD4+ cell count (cells/mm3):
Median 156 158 151 70
Range 1-1893 1-1893 1-702 4-337
Hepatitis co-infection [N (%)]:
HBsAg-/HCV RNA- 1136 (87.5) 1088 (100.0) 37 (20.7) 9 (64.3)
HBsAg+ 55 (4.2) 0 (0.0) 55 (30.7) 2 (14.3)
HCV RNA+ 83 (6.4) 0 (0.0) 83 (46.4) 3 (21.4)
HBsAg+/HCV RNA+ 2 (0.2) 0 (0.0) 2 (1.1) 0 (0.0)
missing 23 (1.8) 0 (0.0) 2 (1.1) 0 (0.0)
Baseline DAIDS Grade ≥2 ALT/AST3 51 (3.9) 0 (0.0) 51 (28.5) 0 (0.0)
1Thirty-two patients had missing information and were unable to be classified into one of the two risk groups. These patients were more likely to 
be female (21.9%) with lower CD4+ counts at baseline (median 121 cells/mm3).
2+LD: patients with underlying liver disease (baseline evidence of active HBV/HCV infection or ALT/AST Grade > 1); -LD: patients with no apparent 
liver disease (absence of active HBV/HCV infection and ALT/AST Grade ≤ 1).
3At baseline, 48 patients had DAIDS Grade 2 ALT/AST, while three patients had DAIDS Grade 3 ALT/AST just prior to first dose of TPV/r.
ALT = alanine aminotransferase; AST = aspartate aminotransferase; DAIDS = Division of AIDS; HBsAg = hepatitis B surface antigen; HBV = 
hepatitis B virus; HCV = hepatitis C virus; TPV/r = ritonavir-boosted tipranavir 500/200 mg BIDBMC Infectious Diseases 2009, 9:203 http://www.biomedcentral.com/1471-2334/9/203
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cumulative risk estimate was 9.5% at 48 weeks (an accu-
mulation of 3.4% additional risk in the period from 24 to
48 weeks). At 72 weeks the cumulative risk was 11.5%
(additional 2.0% in the period from 48 weeks to 72
weeks) and at 96 weeks the cumulative risk was 13.7% (an
additional 2.2%, for 72 to 96 weeks). The proportion of
patients with DAIDS Grade 3/4 transaminase elevations
by Week 96 was lower among -LD patients (10.1%; 110/
1088), compared to +LD patients (16.8%; 30/179). The
K-M cumulative risk for Grade 3/4 ALT/AST elevations
was nearly 2-fold higher in +LD patients compared to
their -LD counterparts at each 24 week interval (Table 2).
Risk factors for DAIDS Grade 3/4 TE
The RESIST 1 and 2 trials were randomized controlled tri-
als that compared responses between TPV/r- based and
comparator PI/r- (CPI/r-) based cART. The design and the
patient population have been described previously
[19,27,28,30,31]. To further understand the association
of risk factors with the development of severe liver
transaminase elevations, Cox regression model was con-
structed. This model examined time to first DAIDS Grade
3/4 ALT and/or AST elevations in RESIST patients, using
96+ week data. Risk factors found to be associated with
time to first Grade 3/4 ALT and/or AST elevations while
controlling for other factors in the model (see Table 3)
included TPV/r treatment (HR: 2.8; p < 0.05), HBV/HCV
co-infection (HR: 2.0; p < 0.05), elevated (DAIDS Grade
≥2) ALT and/or AST at baseline (HR: 2.1; p < 0.10), and
baseline CD4 >200 cells/mm3 (HR: 1.5; p < 0.10).
Two additional Cox models examined only the TPV/r
patients in RESIST 1 and 2, and compared the risk of
DAIDS Grade 3/4 ALT and/or AST elevation in patients
who were either HBV/HCV co-infected or who had DAIDS
Grade  ≥2 for ALT and/or AST at baseline versus those
patients who had neither co-infection nor baseline ALT
and/or AST elevation. The analyses used 96+ week data. In
both comparisons, the risk was significantly elevated (HR:
1.8, p < 0.05) in patients who had co-infection or ≥2
DAIDS Grade ALT and/or AST at baseline (Data not
shown).
Clinical outcomes following Grade 3/4 ALT/AST 
transaminase elevations
Of the 144 patients who developed DAIDS Grade 3/4
ALT/AST elevations by Week 96, there were 123 (85%)
who had no associated symptomatic hepatic events
(asymptomatic). Over this period, 1.6% (21/1299) of
TPV/r 500/200 mg BID recipients developed DAIDS
Grade 3/4 ALT/AST elevations, accompanied by sympto-
matic hepatic AEs (serious and/or non-serious) and 0.3%
(n = 4) of all TPV/r patients developed a hepatic SAE in
association with a DAIDS Grade 3/4 ALT/AST elevation.
The majority (84.0%) of the 144 patients were either able
to continue TPV/r treatment or re-introduce treatment fol-
lowing interruption (Figure 2).
Following the development of DAIDS Grade 3/4 ALT/AST
elevations, 64.6% (93/144) of patients continued TPV/r
treatment without interruption, and in 94.6% of these,
Table 2: Kaplan-Meier estimates for time-to-first DAIDS Grade 3/4 ALT and/or AST elevation and time-to-first hepatic serious 
adverse event (SAE) among TPV/r 500/200 mg patients in trials 1182.12, 1182.48, 1182.51, 1182.52 and 1182.17
96 week CR(%)1 DAIDS2 Grade 3/4 ALT/AST Hepatic SAE
TPV/r
All
N = 1299
TPV/r-LD3
N = 1088
TPV/r +LD3
N = 179
TPV/r
All
N = 1299
TPV/r-LD4
N = 1088
TPV/r+LD4
N = 179
Week 24 6.1 5.4 9.4 0.5 0.5 0.6
Week 48 9.5 8.3 15.6 0.9 0.7 2.1
Week 72 11.5 10.3 17.2 1.1 0.8 3.0
Week 96 13.7 12.5 20.6 1.4 1.0 4.3
1Cumulative rate through 96 weeks.
2DAIDS Grade 3 is defined as ALT/AST = 5.1 to 10 × ULN reference range. DAIDS Grade 4 is defined as ALT/AST >10 × ULN reference range.
3Log-rank test comparing -LD versus +LD patients: p < 0.05.
4Log-rank test comparing -LD versus +LD patients: p < 0.05.
+LD = patients with underlying liver disease (baseline evidence of active HBV/HCV infection or ALT/AST Grade >1); -LD = patients with no 
apparent liver disease (absence of active HBV/HCV infection and ALT/AST Grade ≤ 1); ALT = alanine aminotransferase; AST = aspartate 
aminotransferase; DAIDS = Division of AIDS; HBV = hepatitis B virus; HCV = hepatitis C virus; SAE = serious adverse event; TPV/r = ritonavir-
boosted tipranavir; ULN = upper limit of normalBMC Infectious Diseases 2009, 9:203 http://www.biomedcentral.com/1471-2334/9/203
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ALT/AST returned to Grade 2 or less in a median of 32
days (IQR = 14-84 days), while remaining on treatment.
There were 28/144 (19.4%) patients who had at least one
treatment interruption. For 17/28 (60.7%) patients who
interrupted therapy, elevated transaminases returned to
DAIDS Grade 2 or less after a median of 46 days (IQR =
20-58 days). However, 11/28 (39.3%) patients who had
treatment interruption developed subsequent recur-
rence(s) of DAIDS Grade 3/4 transaminases that led to
discontinuation.
Twenty of the 144 (13.9%) patients with DAIDS Grade 3/
4 ALT/AST elevations discontinued treatment at the first
Grade 3/4 elevation. Three patients developed their first
severe transaminase elevations on the last visit for which
follow-up data were available.
The course of action taken among -LD and +LD TPV/r
patients was similar (Figure 2), with the majority (81/110
[74%] -LD patients; 22/30 [73%] +LD patients) able to
continue, or interrupt and re-introduce, TPV/r treatment
with a subsequent decrease in transaminase elevations to
DAIDS Grade 2 or less. All -LD patients who continued
with TPV/r treatment had transaminase levels return to
DAIDS Grade 2 or less after a median of 29 days. Simi-
larly, among +LD patients who continued with TPV/r
treatment, all but one patient had transaminase levels
decrease to DAIDS Grade 2 or less, although the median
recovery time was longer than in -LD patients (43 days).
Clinical hepatic serious adverse events
Among the 1299 treatment-experienced TPV/r patients,
14 (1.1%) patients experienced hepatic (non-biliary and
non-laboratory) SAEs.
The cumulative risk of clinical hepatic SAEs remained low
through 96 weeks (0.5% at Week 24, 0.9% at Week 48,
and 1.4% at Week 96) (Table 2 and Figure 1). Among -LD
and +LD patients, the cumulative risks of hepatic SAEs
were similar during the first 24 weeks (0.5% and 0.6%,
respectively). However, after Week 24, the risks of clinical
hepatic SAEs increased disproportionately among +LD
patients compared to -LD patients. K-M rates of +LD
patients (Figure 1) increased to 2.1% at Week 48 (an accu-
mulation of 1.5% additional risk from Week 24 to Week
Kaplan-Meier estimates for time-to-first Grade 3/4 ALT/AST elevations and to first hepatobiliary serious adverse events (SAEs)  among TPV/r recipients by baseline risk group Figure 1
Kaplan-Meier estimates for time-to-first Grade 3/4 ALT/AST elevations and to first hepatobiliary serious 
adverse events (SAEs) among TPV/r recipients by baseline risk group. Log-rank test p-value comparing -LD vs. +LD:. 
Incidence of Hepatic SAEs p = 0.0125. Incidence of DAIDS Grade 3/4 ALT/AST p = 0.0072. TPV/r +LD patients with Grade 3/
4 ALT/AST = TPV/r patients co-infected with HBV/HCV or with baseline ALT/AST DAIDS >1, time-to-first DAIDS 3 ALT/
AST. TPV/r -LD patients with Grade 3/4 ALT/AST = TPV/r patients not co-infected with HBV/HCV and with baseline ALT/AST 
DAIDS 1, time-to-first DAIDS 3 ALT/AST. TPV/r +LD patients with hepatic SAE = TPV/r patients co-infected with HBV/HCV 
or with baseline ALT/AST DAIDS >1, time-to-first onset date of hepatic SAE. TPV/r -LD patients with hepatic SAE = TPV/r 
patients not co-infected with HBV/HCV and with baseline ALT/AST DAIDS 1, time-to-first onset date of hepatic SAE. +LD = 
patients with underlying liver disease (baseline evidence of active HBV/HCV infection or ALT/AST DAIDS >1); -LD = patients 
with no apparent liver disease (absence of active HBV/HCV infection and ALT/AST Grade ≤ 1); ALT = alanine aminotrans-
ferase; AST = aspartate aminotransferase; DAIDS = Division of AIDS; HBV = hepatitis B virus; HCV = hepatitis C virus; TPV/r 
= ritonavir-boosted tipranavir.
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48), to 3.0% at Week 72 (accumulated additional risk of
0.9% from Week 48 to 72), and to 4.3% at Week 96 (accu-
mulated additional risk of 1.3% from Week 72 to 96). For
-LD patients, the corresponding accumulation of addi-
tional risk was 0.2% from Week 24 to Week 48, 0.1%
from Week 48 to 72, and 0.2% from Week 72 to 96.
Among the +LD patients there were 5/179 (2.8%) with
hepatic SAEs; two with hepatic failure, one with hepatic
steatosis, one with hepatocellular damage and one with
isolated hyperbilirubinemia. All five were co-infected
with HBV or HCV. There were 9/1088 -LD patients (0.8%)
with hepatic SAEs; four with hepatic failure, two with
hepatotoxicity or toxic hepatitis, and one patient each
with steatosis, cirrhosis, hepatosplenomegaly.
Among all 1299 TPV/r-treated patients, six (0.5%) had a
hepatic SAE denoting hepatic failure. Five had fatal out-
comes. These events occurred in patients with concomi-
tant end-stage AIDS events, including disseminated
Mycobacterium avium intracellulare, visceral leishmaniasis,
Burkitt's lymphoma, squamous carcinoma, sepsis and
multi-organ failure. The sixth patient recovered rapidly
and was discharged from the hospital after five days, sug-
gesting the diagnosis may have not been entirely accurate.
An apparent higher risk among hepatitis co-infected
patients was observed; two of the six hepatic failure cases
occurred among hepatitis co-infected patients (1.4%)
while four occurred among non-hepatitis co-infected
patients (0.4%; data not shown). In all but one case, the
extent of the role of TPV in the development of liver fail-
ure is uncertain.
The occurrence of Grade 3/4 ALT/AST elevations and clin-
ical hepatic SAEs among TPV/r 500/200 mg BID patients
who were -LD and +LD is presented in Table 4. Of the 144
patients who developed Grade 3/4 ALT/AST elevations,
four subsequently developed a hepatic SAE through 96
weeks, suggesting that transaminase elevations may be a
poor predictor of clinical hepatic SAEs (positive predictive
value [PPV]: 2.8%). The +LD patients had a PPV of just
3.3%, with only 1/30 patients with Grade 3/4 ALT/AST
elevations developing a hepatic SAE. The -LD patients had
a PPV of 2.7%, with 3/110 patients with a Grade 3/4 ALT/
AST elevation through 96 weeks developing a hepatic SAE.
Among -LD and +LD patients treated with TPV/r 500/200
mg BID in the five trials comprising the TPV/r develop-
ment program, monitoring of transaminase elevations to
determine which patients may be at risk for clinical
hepatic SAEs appears to have limited value, with corre-
sponding sensitivity values of 33.3% and 20.0%. In both
patient groups, regardless of the development of Grade 3/
4 ALT/AST elevation, the large majority of patients did not
experience a clinical hepatic SAE.
Discussion and Conclusions
The goal of cART is to achieve durable HIV suppression
and sustained improvements in immune function by the
delivery of an ARV regimen that also provides adequate
safety and tolerability. Adverse events are associated with
all ARV agents and may influence decisions to switch or
discontinue therapy. Since some individuals may be pre-
disposed to ARV therapy-associated AEs, safety considera-
tions should take into account underlying conditions,
concomitant medications and history of drug intolerance
[11]. All ARV drugs have been associated with develop-
ment of Grade 3/4 ALT/AST elevations [11,32]; and these
events are more frequent in patients with HBV/HCV co-
infection or increased baseline hepatic transaminase lev-
Table 3: Cox regression for time to first occurrence of DAIDS Grade 3 or 4 ALT and/or AST abnormalities in TPV/r-based and 
comparator PI/r- (CPI/r-) based cART RESIST patients
Parameter HR1 (p-value) 95% Confidence Interval
Treatment group: 2.77 (<0.0001) 1.71, 4.48
TPV/r v CPI/r
HBV or HCV co-infection: 2.00 (0.0057) 1.22, 3.27
yes vs. no
ALT/AST at baseline: 2.05 (0.0709) 0.94, 4.48
Grade ≥2 vs. ≤Grade 1
CD4+ cells at baseline: 1.46 (0.0643) 0.98, 2.18
>200 vs. ≤200 cells/mm3
1 Hazard Ratio
Model further controlled for sex, race and concurrent use of T-20 (none were statistically significant).BMC Infectious Diseases 2009, 9:203 http://www.biomedcentral.com/1471-2334/9/203
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els [11,32-34]. However, the cause of liver enzyme eleva-
tions is often unclear, particularly among HIV-infected
individuals with advanced disease. Further, in some
asymptomatic individuals, elevated transaminases may
resolve spontaneously despite continued drug treatment
[35]. This may reflect an adaptive host response as seen
with some drugs causing hepatotoxicity [36,37].
The development of DAIDS Grade 3/4 transaminase ele-
vations and clinical hepatic SAEs in treatment-experi-
enced HIV-positive patients receiving ARV therapy with
TPV/r 500/200 mg BID varies according to baseline factors
that define -LD and +LD patients. The K-M cumulative risk
estimate of patients with DAIDS Grade 3/4 elevations by
Week 96 was lower among the -LD patients (12.5%),
compared to the +LD patients (20.6%).
The large majority of TPV/r patients who developed
DAIDS Grade 3/4 ALT/AST elevations remained asympto-
matic and did not develop clinical signs or symptoms of
liver-related SAEs. Among -LD patients, the cumulative
risk of experiencing a hepatic SAE was low (1.0%) through
96 weeks of treatment, with most occurring in the first 6
months. As expected, +LD patients tended to have a
greater risk of developing a hepatic SAE than -LD patients.
Per protocol, any patient experiencing DAIDS 4 toxicity,
according to the GCP and ICH guidelines, was to be dis-
Actions and outcomes of Grade 3/4 ALT/AST elevations among TPV/r recipients Figure 2
Actions and outcomes of Grade 3/4 ALT/AST elevations among TPV/r recipients. TPV/r +LD patients = TPV/r 
patients co-infected with HBV/HCV or with baseline ALT/AST DAIDS >1. TPV/r -LD patients = TPV/r patients not co-infected 
with HBV/HCV and with baseline ALT/AST DAIDS 1. +LD = patients with underlying liver disease (baseline evidence of active 
HBV/HCV infection or ALT/AST DAIDS >1); -LD = patients with no apparent liver disease (absence of active HBV/HCV infec-
tion and ALT/AST Grade ≤ 1); ALT = alanine aminotransferase; AST = aspartate aminotransferase; HBV = hepatitis B virus; 
HCV = hepatitis C virus; IQR = interquartile range; TPV/r = ritonavir-boosted tipranavir.
All TPV/ r1,2
N=144
Achieving Grade  2
n=17 (60.7%)
Median days to Grade  2
46
IQR
20-58
Grade 3/ 4 after re-
challenge
n=11 (39.3%)
Achieving Grade  2
n=88 (94.6%)
Median days to Grade 
2
32
IQR
14-84
Not reaching Grade  2
n=5 (5.4%)
–
Continue
n=93 (64.6%)
Interrupt
n=28 (19.4%)
Discontinue
n=20 (13.9%)
TPV/ r -LD
N=110
Achieving Grade  2
n=13 (56.5%)
Median days to Grade  2
50
IQR
35-58
Grade 3/ 4 after re-
challenge
n=10 (43.5%)
Achieving Grade  2
n=68 (94.4%)
Median days to Grade  2
29
IQR
14-83
Not reaching Grade  2
n=4 (5.6%)
–
Continue
n=72 (65.5%)
Interrupt
n=23 (20.9%)
Discontinue
n=13 (11.8%)
TPV/ r + LD
N=30
Achieving Grade  2
n=4 (100.0%)
Median days to Grade  2
14.5
IQR
8-42
Grade 3/ 4 after re-
challenge
n=0 (0.0%)
Achieving Grade  2
n=18 (94.7%)
Median days to Grade 
2
43
IQR
8-83
Not reaching Grade  2
n=1 (5.3%)
–
Continue
n=19 (63.3%)
Interrupt
n=4 (13.3%)
Discontinue
n=6 (20.0%)
1. Of the 144 patients with Grade 3 ALT/AST, four patients could not be categorized as +LD or -LD due to missing baseline data for HBV/HCV and/or 
baseline ALT/AST. Therefore, the patient numbers in the -LD and +LD boxes will not add up to the total in the All TPV/r box.
2. Of the 144 patients with Grade 3/4 ALT/AST, three patients could not be categorized as they had their first elevation on the last visit day.BMC Infectious Diseases 2009, 9:203 http://www.biomedcentral.com/1471-2334/9/203
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continued from treatment. However, the patient popula-
tion consisted of patients with advanced stage of HIV
disease, presenting with opportunistic infections and the
TPV/r was their last option for treatment. These compas-
sionate trial designs were developed and approved by the
regulatory authorities and key opinion leaders and the
continued treatment despite toxicity was a decision
between the principal investigator and the patient on a
case by case basis with very close patient monitoring. Con-
sequently, many patients who developed DAIDS Grade 3/
4 ALT/AST elevations on TPV/r therapy were able to con-
tinue treatment uninterrupted or resume treatment after
temporary discontinuation, with transaminase levels
returning to DAIDS Grade 2 or less during the treatment
period. Interestingly, changes in serum ALT/AST transam-
inase levels associated with TPV/r treatment were not typ-
ically predictive of the development of clinical hepatic
SAEs. This lack of association of serum ALT/AST levels and
clinical events has been observed with other medications.
For example, at an FDA-AASLD-PhRMA (Food and Drug
Administration-American Association for the Study of
Liver Diseases-Pharmaceutical Research and Manufactur-
ers of America) meeting on drug hepatotoxicity [36], it
was pointed out that some drugs, such as isoniazid, are
associated with a high risk of substantial transaminase ele-
vations. However, these transaminase elevations are not
strongly predictive of clinical hepatic events (low PPV)
and clinical monitoring has become increasingly more
important than laboratory monitoring. Nevertheless,
transaminase elevations are a marker for hepatocellular
liver injury so, despite poor PPV, increased transaminase
monitoring is likely to be of value in +LD patients in
whom the clinical significance of hepatic injury may be
greater.
Multivariate analyses revealed hepatitis co-infection and
baseline liver impairment being independently associated
with increased risk of severe liver transaminase elevations.
Others have also identified chronic viral hepatitis and
abnormal baseline liver enzyme levels as risk factors for
increased risk of hepatotoxicity with other ARV regimens
[9,11,16,20,21,23,35,38-41]. The association between
CD4+ > 200 cells/mm3 at baseline and the subsequent risk
of developing DAIDS 3/4 TE while on treatment may have
resulted from a bias. It is possible that the "healthier"
patients with higher CD4+ cell count at baseline remained
on study longer than the sicker patients and therefore had
more transaminase testing performed, and thus increasing
the possibility of detection of elevated transaminases. In
our study, patients with CD4+ counts > 200 cell/mm3
remained in the study nearly 3.5 months longer than
patients with counts at or below 200 cells/mm3. The over-
all drug exposure difference is more pronounced when
one considers treatment regimen; on the average TPV/r
patients with CD4+ counts above 200 remained in the
study 8 month longer than their CPI/r treated counter-
parts (data not shown).
Inherent in many clinical trials are limitations in captur-
ing all of the necessary risk factors associated with the out-
come being evaluated. Although safety of patients was of
paramount importance, the focus of these trials was on
efficacy in a cohort of patients with highly advanced HIV
disease and limited treatment options. As such, baseline
information on known risk factors for hepatotoxicity,
such as allergic predisposition, severe hepatic steatosis or
hepatic cirrhosis [8] was obtained only through investiga-
tor and/or patient self-reporting; and therefore may have
led to an underestimation of the presence of pre-existent
liver disease, and hence an underestimation of the contri-
bution of these to observed serious hepatic events associ-
ated with tipranavir in patients. In these trials, the
baseline prevalence of any reported hepatic steatosis, cir-
rhosis or drug hypersensitivity was too low, 0.5% (6/
1299), 0.2% (2/1299) and 1.9% (25/1299), respectively,
to warrant evaluation of these important risk factors.
Another limitation to these analyses, found in HIV clinical
studies in general, is the predominance of male patients.
In the tipranavir Phase IIb and III clinical trials, only 10%
of all patients were females, possibly limiting our ability
to fully examine the role of gender on our study results
and conclusions. While some researchers have shown a
differential incidence of drug-related adverse events [42-
44] based on gender, these results have not been con-
firmed by others [45,46].
Table 4: Occurrence of DAIDS Grade 3/4 ALT/AST and hepatic 
serious adverse events (SAEs) among -LD and +LD TPV/r 500/
200 mg BID patients
-LD patients1 +LD patients1
ALT/AST DAIDS >22 Hepatic SAE Hepatic SAE
Yes No Yes No
Yes 3 107 1 29
No 6 970 4 141
1Thirty-two patients had missing information and were unable to be 
classified into one of the two risk groups; none of these patients 
experienced a hepatic SAE.
+LD = patients with underlying liver disease (baseline evidence of 
active HBV/HCV infection or ALT/AST Grade >1); -LD = patients 
with no apparent liver disease (absence of active HBV/HCV infection 
and ALT/AST Grade ≤ 1); ALT = alanine aminotransferase; AST = 
aspartate aminotransferase; DAIDS = Division of AIDS; HBV = 
hepatitis B virus; HCV = hepatitis C virus; TPV/r = ritonavir-boosted 
tipranavir
2ALT/AST on treatment DAIDS Grade 3/4BMC Infectious Diseases 2009, 9:203 http://www.biomedcentral.com/1471-2334/9/203
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In conclusion, TPV/r-based cART was associated with
DAIDS Grade 3/4 ALT/AST elevations in treatment-experi-
enced, HIV-1-infected patients with HIV advanced disease
and limited treatment options; patients with elevated
baseline ALT and/or AST levels and/or chronic viral hepa-
titis had the greatest risk. Of note, most of these transam-
inase elevations were not associated with clinically
significant events; most patients with elevated transami-
nases experienced resolution without permanent discon-
tinuation of TPV/r. Furthermore, Grade 3/4 ALT/AST
elevations were not predictive of subsequent clinical
hepatic events because the majority of patients remained
asymptomatic. In this highly ARV-experienced patient
population, the risk of DAIDS Grade 3/4 ALT/AST eleva-
tions should be balanced with the potential benefit of
treatment with TPV/r in individuals for whom this repre-
sents an active ARV drug. Importantly, TPV/r demon-
strated significantly greater virologic response than CPI/r
in the RESIST trials, which enrolled more than 1400 treat-
ment-experienced patients [6,30]. Further follow-up of
these trials has indicated that TPV/r patients who achieve
virologic suppression continue to do well through 156
weeks of treatment [31].
For HIV-positive patients being treated with TPV/r, health-
care providers should monitor patients for the emergence
of clinically significant hepatic events. Appropriate labo-
ratory and clinical monitoring should be conducted prior
to initiating therapy with TPV/r, and throughout treat-
ment. Increased frequency of monitoring should be con-
sidered when TPV/r is administered to patients with
elevated baseline ALT/AST levels, or active HBV/HCV co-
infection, as these patients may be at increased risk for
developing further transaminase elevations.
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